Patients with inflammatory bowel disease (IBD) who had primary nonresponse ─ or inadequate response to the initial loading doses ─ to an anti-tumour necrosis factor (TNF) agent were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.
Obesity does not appear to have a significant influence on treatment response and clinical outcomes in patients with inflammatory bowel disease (IBD), according to two studies presented at the 2018 Crohn’s & Colitis Congress (CCC).
Use of the gut-selective anti-integrin monoclonal antibody vedolizumab was associated with favourable treatment outcomes in patients with inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease, according to studies presented at the 2018 Crohn’s & Colitis Congress (CCC).
Using the JAK* inhibitor tofacitinib as induction therapy for Crohn’s disease (CD) can promote disease remission in certain patients selected based on baseline endoscopic evidence of inflammation, according to a post hoc analysis presented at the recent Crohn's & Colitis Congress (CCC) 2018, Las Vegas, Nevada, US.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.